Search
SF Healthcare Week: Rachel Haurwitz shares an update on Caribou Biosciences' allo CAR-T programs in NHL, multiple myeloma, and lupus
She describes how the company's HLA matching and CD19 relapse testing is playing out, when we can expect to see new data, and how the...
Jan 15
SF Healthcare Week: The CEO of Arvinas talks protein degradation, including about the industry's first phase 3 readout that is upcoming this quarter
John Houston describes what he believes are the keys to protein degradation, and discusses the company's monotherapy and combination...
Jan 15
SF Healthcare Week: After striking a transformational deal with Sanofi, Novavax is ramping up its vaccine pipeline
CEO John Jacobs describes the Sanofi deal, and combining Covid vaccines with flu vaccines. Plus, how the company is thinking about...
Jan 14
SF Healthcare Week: The CEO of Akeso talks about its PD1xVEGF, other bi-specific targets, and her opinion of China's position in the global biotech ecosystem
Chairman & CEO Michelle Xia describes the clinical trial that was run comparing the company's PD1xVEGF vs Akeso, development plans...
Jan 14
SF Healthcare Week: With two commercial products providing cash flow, and more in development, the new CEO of Acadia Pharma is ready to do deals
Catherine Owen Adams walks us through the latest on NUPLAZID and DAYBUE, and products in development for Alzheimer's psychosis,...
Jan 14
SF Healthcare Week: Roivant CEO Matt Gline provides an update on the 'vant ecosystem
He discusses key data in the year ahead including from Immunovant and Priovant. Plus, an update on the lawsuits regarding covid vaccine...
Jan 13
SF Healthcare Week: Teva CEO Richard Francis discusses the TL1A space, and the how company's overall focus has transformed to innovation
He describes how he believes the TL1A compares to others in the field, other programs in the company's innovation pipeline, and the...
Jan 13
SF Healthcare Week: Verve's CEO on the company's two clinical programs, and more in the pipeline
Sek Kathiresan provides an update on the company's PCSK9 and ANGPTL3 clinical programs, as well for the preclinical LPA program.
Jan 12
Candid Therapeutics licensed a trispecific T-cell engager from WuXi Biologics today for autoimmune disease. Chairman & CEO Ken Song talks about T-cell engagers vs CAR-Ts for autoimmune
He describes two clinical programs that Candid currently has targeting BCMA and CD20. Plus, discovery programs with U.S. and China based...
Jan 6
PureTech Health's CEO and Co-Founder discuss this week's IPF data, the approval of Cobenfy in schizophrenia, and the company's unique hub and spoke business model
CEO Bharatt Chowrira and Co-Founder Eric Elenko describe the unmet need in IPF that exists today, and how their drug deupirfenidone was...
Dec 18, 2024
Cardiff Oncology CEO Mark Erlander discusses last week's data for the PLK1 inhibitor onvansertib in first-line RAS-mutated mCRC
He describes the rationale for PLK1 inhibition and highlights the significance of the data, which will have an additional update next...
Dec 16, 2024
Syndax's CEO Michael Metzger talks about the approvals of Revuforj and Niktimvo, moving both into other settings, competition, and more
He describes being first to market in the menin inhibitor space and the advantage he believes that gives Syndax, and he highlights other...
Dec 16, 2024
Seattle based Seal Rock Therapeutics is working on a second-generation ASK1 inhibitor that is designed to improve on the safety profile of the class and could have utility in a range of liver diseases
Co-founder and CEO Neil McDonnell describes the history of ASK1 and how Seal Rock's program has been optimized to avoid roadblocks that...
Dec 13, 2024
Seattle and San Carlos, CA based Nautilus Biotechnology is developing a platform that aims to revolutionize how researchers are able to see the proteome. CEO Sujal Patel tells us how it will work
He describes the shortcomings of high affinity assays and mass spectometry, and how the Nautilus system will be different. Plus, use...
Dec 12, 2024
Seattle based Lumen Bioscience is using the cyanobacteria spirulina to manufacture medicines, which might increase the yield and lower the cost of biologics. Its pipeline includes an obesity program
CEO Brian Finrow describes the characteristics of spirulina that Lumen believes will make it the next new paradigm in developing and...
Dec 12, 2024
Seattle based Umoja Biopharma is a pioneer of in vivo CAR-T cell engineering. CEO Andrew Scharenberg describes the technical innovations they have come up with to help make it succeed
He describes Umoja's numerous platforms that are aimed at maximizing in vivo success, including the company's proprietary lentiviral...
Dec 11, 2024
ASH 2024: France's MaaT Pharma presented early access data at ASH for its microbiome based treatment for GvHD - a formal study will read out early next year
CMO Gianfranco Pittari describes the unmet neet in GvHD and how the donor derived microbiome treatment is designed to work. A patient has...
Dec 10, 2024
ASH 2024: Nurix Therapeutics' CEO Arthur Sands talks BTK degradation vs inhibition and the company's broader pipeline of degraders
He discusses Nurix's clinical data set that was presented at ASH. Plus, the company's pipeline, including in the autoimmune space, and...
Dec 10, 2024
ASH 2024: Disc Medicine's CEO shares an update on three programs, including an oral presentation for an anti-anemia antibody for patients with myelofibrosis and potentially beyond in the future
John Quisel shares an update on ASH data for DISC-0974, bitopertin, and DISC-3405.
Dec 10, 2024
Neurvati Neurosciences is a Blackstone owned development company that focuses on late stage assets in neuroscience - the first project targets an NMDA subunit, called NR2B, for GRIN disorders
CEO Bruce Leuchter, a physician trained in neurology and psychiatry himself, describes the rational and structure behind Neurvati, and...
Dec 9, 2024
.png){kind=logo}
